Product Overview

Clomisign 50 mg is a pharmaceutical formulation containing the active ingredient clomiphene citrate, indicated for the treatment of female infertility. Manufactured by HAB Pharmaceuticals & Research Ltd, each strip contains ten tablets of 50 mg strength. The product is marketed in various pack sizes, including 100, 200, and 300 tablets, to accommodate different treatment regimens. Clomisign belongs to the class of selective estrogen receptor modulators (SERMs) and is widely used to stimulate ovulation in women who experience ovulatory dysfunction.

What is Clomisign 50 mg

Clomisign 50 mg is the branded version of clomiphene citrate, a non‑steroidal compound that acts as a partial agonist/antagonist at estrogen receptors in the hypothalamus and pituitary gland. By blocking estrogen feedback, it increases the release of gonadotropin‑releasing hormone (GnRH), which in turn prompts the anterior pituitary to secrete follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). This hormonal surge promotes the development and maturation of ovarian follicles, potentially leading to ovulation in women with infertility due to anovulation or oligo‑ovulation.

Uses and Benefits

The primary clinical use of Clomisign is to induce ovulation in women diagnosed with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or other forms of ovulatory dysfunction. In addition to its ovulation‑inducing properties, Clomisign may be employed off‑label in certain assisted reproductive technologies (ART) protocols, such as controlled ovarian hyperstimulation, to increase the number of mature oocytes retrieved for egg collection. Clinical studies have demonstrated that treatment with clomiphene citrate can improve pregnancy rates compared with placebo in appropriately selected populations. However, success rates vary based on age, baseline ovarian reserve, and underlying diagnosis.

How It Works

The mechanism of action of clomiphene citrate involves selective antagonism of estrogen receptors in the central nervous system. When estrogen receptors in the hypothalamus are blocked, the negative feedback loop is disrupted, resulting in increased GnRH pulsatility. This stimulates the pituitary gland to release higher amounts of FSH and LH, which act on the ovaries to promote follicular growth. The dual agonist/antagonist effect allows clomiphene to mimic estrogenic activity in peripheral tissues while exerting anti‑estrogenic effects in the brain, a property that distinguishes it from other SERMs.

Dosage Guidelines

Clomisign is typically administered orally once daily for five consecutive days, beginning on the third to fifth day of the menstrual cycle in women who are still menstruating. The standard starting dose is 50 mg (one tablet) per day; however, some clinicians may increase the dose to 100 mg per day in subsequent cycles if ovulation does not occur and tolerability is confirmed. Dosage adjustments should only be made under the supervision of a qualified healthcare professional. It is essential to adhere to the prescribed duration and not to exceed the recommended course, as prolonged use may increase the risk of ovarian hyperstimulation and other adverse events. Patients should be advised to consult their physician before altering any dosing schedule.

Side Effects

Common side effects associated with Clomisign include hot flashes, abdominal discomfort, breast tenderness, nausea, and visual disturbances such as blurred vision or flashing lights. Less frequent but clinically significant adverse reactions may involve ovarian hyperstimulation syndrome (OHSS), which can present with pelvic pain, ascites, and shortness of breath. Rarely, thromboembolic events have been reported. Most side effects are mild to moderate and resolve spontaneously after discontinuation of the medication. Patients experiencing severe or persistent symptoms should seek medical attention promptly.

Warnings and Precautions

Clomisign should not be used in individuals with known hypersensitivity to clomiphene citrate or any of the excipients in the formulation. It is contraindicated in patients with liver disease, ovarian cysts unrelated to polycystic ovary syndrome, and uncontrolled endocrine disorders. Prior to initiation, a thorough medical evaluation—including a pelvic exam and assessment of ovarian reserve—should be performed. Women who are pregnant, breastfeeding, or have a history of estrogen‑dependent tumors should avoid treatment. Clinicians are advised to monitor patients for signs of OHSS and to adjust dosing accordingly. Concurrent use of other hormonal therapies should be reviewed for potential interactions.

FAQs

1. What is the typical success rate of Clomisign in inducing ovulation?
   Clinical trials have shown that approximately 70% of women with polycystic ovary syndrome will ovulate after a course of clomiphene citrate, and about 30% achieve clinical pregnancy within six treatment cycles.
2. Can Clomisign be used in women over the age of 35?
   Clomisign is generally considered safe for women of reproductive age, but success rates tend to decline with advancing maternal age. Physicians may consider alternative ovulation induction agents or adjunctive therapies for older patients.
3. Is Clomisign associated with an increased risk of multiple pregnancies?
   Yes, the use of clomiphene can increase the likelihood of twins or higher-order multiples, although the absolute risk remains low. Close monitoring during treatment helps mitigate this risk.
4. Do I need a prescription to purchase Clomisign?
   Clomisign is a prescription‑only medication in most jurisdictions. It should be obtained through a licensed healthcare provider who can evaluate suitability and monitor treatment.
5. Where can I find more detailed scientific information about clomiphene citrate?
   Comprehensive data are available through resources such as the National Institutes of Health (NIH), PubMed, and the U.S. Food and Drug Administration (FDA) label for clomiphene citrate.

For additional authoritative information, refer to the MedlinePlus entry on clomiphene, the FDA prescribing information, and peer‑reviewed articles indexed on PubMed.

Patients are encouraged to discuss any questions or concerns with their healthcare provider to ensure safe and effective use of Clomisign 50 mg.

Related Products

• Tretoin 0.1% Gel (Tretinoin)
• Tretoin 0.025% Cream (Tretinoin)
• Tretoin 0.05% Cream (Tretinoin)
• Tretinex Cream (Tretinoin)
• Tretoin Cream (Tretinoin)
• Naltrexone 50 mg (Naltrexone)
• Methylprednisolone (Signapred 4 mg)
• Signapred 4 mg (Methylprednisolone)
• Griseofulvin 500 mg (Generic)
• Lamifil 250 Mg (Terbinafine)
• Fungicyte 150 (Fluconazole 150mg)
• Dermozole 500 mg (Griseofulvin)